Compare Summit Therapeutics Inc (SMMT) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Summit Therapeutics Inc trades at $17.38 (market cap $13.71B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.48 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 5.3× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| SMMT | VTIP | |
|---|---|---|
Market Cap | $13.71B | $73.20B |
Volume | 6,173,057 | 2,511,360 |
Sector | Health | — |
52-Week High | $26.38 | $50.46 |
52-Week Low | $12.43 | $48.38 |
Typical Hold Time | 16 Days | 91 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.475, up 0.03% on the day. Technical indicators show a bearish bias with moving averages signaling sell pressure, while oscillators like the 6-day relative strength index at 15.33 suggest oversold conditions. Recent news highlights its role as an inflation hedge amid rising energy prices and Fed rate hikes. The ETF focuses on short-duration TIPS to minimize interest rate risk, with institutional buying noted in recent SEC filings.
The outlook for VTIP is cautiously positive as a defensive inflation hedge, with real yields at multi-decade highs boosting appeal. However, risks include persistent inflation above the Fed's target and potential volatility from rate uncertainty. Investors seeking low-cost, short-duration inflation protection may find value, but the bearish technical trend warrants monitoring for stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
